- Home
- VHUB vs LIXT Comparison
VHUB vs LIXT Comparison
Compare VHUB & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VHUB | LIXT |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.8M | 107.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VHUB | LIXT |
|---|---|---|
| Price | $1.02 | $7.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 136.6K | ★ 594.5K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $2.45 |
| 52 Week High | $15.34 | $8.38 |
Technical Indicators
Market Signals| Indicator | VHUB | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 43.33 | 54.53 |
| Support Level | $0.58 | $6.21 |
| Resistance Level | $1.38 | $7.64 |
| Average True Range (ATR) | 0.12 | 0.84 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 41.74 | 53.35 |
Price Performance
Historical ComparisonAbout VHUB VenHub Global Inc. Common Stock
Venhub Global Inc is engaged in designing and building autonomous Smart Stores that operate 24/7 without on-site staff. Each store combines robotic automation, real-time inventory tracking, and mobile-based checkout to provide secure, convenient retail access, and is offered as an integrated retail solution to store operators.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.